Erasmus University Medical Center | Erasmus Infectious Diseases
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-CD123 in patients with hematologic and lymphatic malignancies positive for CD123 marker. The UniCAR02-T-CD123 drug is a combination of a cellular component (UniCAR02-T) with a recombinant antibody derivative (TM123) which together forms the active drug.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
90 participants in 2 patient groups
Loading...
Central trial contact
Antje Warth, Dr.; Martin Lorkowski, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal